ANVS
Ticker
Annovis Bio, Inc.
ANVS · Healthcare · Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United StatesAnnovis Bio, Inc. (ANVS), in the Healthcare sector, has 8 disclosed filings on Paydirt over the trailing twelve months from 2 corporate insiders: 8 purchases and 0 sales, 2 filed past the deadline. Filers took a median of 1 day from execution to disclosure, and the most recent trade was executed Nov 6 and filed Nov 6. The most active filer was Michael B Hoffman with 7 filings. Data as of Nov 7 2026.
Add to watchlistFilings, ttm
8
8 buys · 0 sells · 2 late
Traders, ttm
2
2 insiders
Volume, ttmiDollar value disclosed in the window
$6.7M
estimated for Congress, as filed for insiders
Median delay
1d
execution to disclosure
Last traded
Nov 6
Filed yesterday
ADViAverage daily dollar volume
$1.2M
market data
Share price · 12M
$0.84 (-57.5%)
Adjusted for splits and dividends.
Volume by month
Buys $9.2M
Sells $0
Estimated for Congress, as filed for insiders · by filing month · past 24 months
Who filed · past 24 months
MHRecent filings
Michael B HoffmanPURCHASE
Director
$5.0M5,000,000 sh × $1.00
Exec Nov 6
Filed Nov 6 · 4:30 PM ET Michael B HoffmanPURCHASE Director $104K
54,933 sh × $1.90
Exec May 20
Filed May 21 · 8:11 PM ET Michael B HoffmanPURCHASE Director $1.5M
713,800 sh × $2.10
Exec Apr 2
Filed Apr 3 · 5:06 PM ET Michael B HoffmanPURCHASE Director $130K
30,000 sh × $4.34
Exec Dec 8 2025
Filed Dec 8 2025 · 8:05 PM ET Michael B HoffmanPURCHASE Director $117K
28,096 sh × $4.15
Exec Nov 24 2025
Filed Nov 25 2025 · 6:59 PM ET Michael B HoffmanPURCHASE Director $117K
28,096 sh × $4.15
Exec Nov 24 2025
Filed Nov 25 2025 · 12:26 PM ET Maria-Luisa MaccecchiniPURCHASE President & CEO $200K
97,561 sh × $2.05
Exec Oct 28 2025
Filed Nov 12 2025 · 9:19 AM ET † Michael B HoffmanPURCHASE Director $2.0M
975,610 sh × $2.05
Exec Oct 28 2025
Filed Nov 12 2025 · 9:18 AM ET †